The effect of PSA level on distant metastases and cause-specific mortality was assessed in a recent study, and showed a nadir PSA level 1.5 ng/ml within 2 years of radiotherapy treatment predicts distant metastases and death from prostate cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Zelefsky, M. J. et al. Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality. Int. J. Radiat. Oncol. Biol. Phys. 75, 1350–1356 (2009).
The NCCN Clinical Practice Guidelines in Oncology™ Prostate Cancer (Version 1.2010) [online]. (2010).
Buyyounouski, M. K., Hanlon, A. L., Horwitz, E. M., Uzzo, R. G. & Pollack, A. Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation. Int. J. Radiat. Oncol. Biol. Phys. 61, 1291–1298 (2005).
Zietman, A. L. et al. Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1–2 adenocarcinoma of the prostate. Radiother. Oncol. 40, 159–162 (1996).
Lee, W. R., Hanlon, A. L. & Hanks, G. E. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival. J. Urol. 156, 450–453 (1996).
Cavanaugh, S. X. et al. Time and PSA threshold model prognosticates long-term overall and disease-specific survival in prostate cancer patients as early as 3 months after external beam radiation therapy. Prostate Cancer Prostatic Dis. 8, 353–358 (2005).
Ray, M. E. et al. Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure. Urology 68, 1257–1262 (2006).
Alcantara, P., Hanlon, A., Buyyounouski, M. K., Horwitz, E. M. & Pollack, A. Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death. Cancer 109, 41–47 (2007).
Buyyounouski, M. K., Hanlon, A. L., Horwitz, E. M. & Pollack, A. Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 70, 59–66 (2008).
Buyyounouski, M. K., Pickles, T., Kestin, L., Allison, R. & Williams, S. G. Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 75, S103–S104 (2009).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Buyyounouski, M. PSA nadir predicts long-term mortality. Nat Rev Clin Oncol 7, 188–190 (2010). https://doi.org/10.1038/nrclinonc.2010.33
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2010.33